Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

NCT ID: NCT04048876

Last Updated: 2023-06-07

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-08-14

Study Completion Date

2021-09-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter, multinational, dose-finding study evaluating the efficacy of three treatment doses of CC-90001 compared with placebo, in Non-alcoholic Steatohepatitis (NASH) participants with Stage 2, Stage 3 liver fibrosis.

This study is designed to assess response to treatment on measures of fibrosis and other efficacy parameters. It will also assess dose response and overall safety.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-alcoholic Fatty Liver Disease Liver Cirrhosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CC-90001 400 mg once daily (QD)

CC-90001 400 mg QD

Group Type EXPERIMENTAL

CC-90001

Intervention Type DRUG

oral

CC-90001 200 mg once daily

CC-90001 200 mg QD

Group Type EXPERIMENTAL

CC-90001

Intervention Type DRUG

oral

CC-90001 100 mg once daily

CC-90001 100 mg QD

Group Type EXPERIMENTAL

CC-90001

Intervention Type DRUG

oral

Placebo once daily

Placebo QD

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

oral

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CC-90001

oral

Intervention Type DRUG

Placebo

oral

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

1. History or evidence of decompensated liver disease,
2. Hepatitis and fibrosis more likely related to etiologies other than non-alcoholic steatohepatitis (NASH).
3. Participant has urine ethyl glucuronide (EtG) \> 500 ng/mL at Screening.
4. History or positive screen for human immunodeficiency virus (HIV) infection or congenital or human immunodeficiency virus (HIV)-unrelated acquired immunodeficiencies (eg, common variable immunodeficiency \[CVID\]).
5. History of hepatitis B and/or hepatitis C.
6. History of malignancy within the last 5 years (exceptions: excised and cured basal/squamous cell skin carcinomas and cervical carcinoma in situ).
7. Pregnancy or lactation.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Celgene

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bristol-Myers Squibb

Role: STUDY_DIRECTOR

Bristol-Myers Squibb

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Saint Joseph's Hosptial and Medical Center - Barrow Neurological Institute

Phoenix, Arizona, United States

Site Status

Mayo Clinic Phoenix

Phoenix, Arizona, United States

Site Status

UC San Diego School of Medicine

La Jolla, California, United States

Site Status

Cedars-Sinai Comprehensive Transplant Center

Los Angeles, California, United States

Site Status

California Liver Research Institute

Pasadena, California, United States

Site Status

Inland Empire Liver Foundation

Rialto, California, United States

Site Status

University of California Davis Medical Center

Sacramento, California, United States

Site Status

Southern California GI & Liver Centers

San Clemente, California, United States

Site Status

University of Colorado, School of Medicine - Hepatology Clinic - Anschutz

Aurora, Colorado, United States

Site Status

Peak Gastroenterology Associates

Colorado Springs, Colorado, United States

Site Status

South Denver Gastroenterology

Englewood, Colorado, United States

Site Status

Bridgeport Hospital

Bridgeport, Connecticut, United States

Site Status

Yale Cancer Center

New Haven, Connecticut, United States

Site Status

Florida Digestive Health Specialists

Lakewood Rch, Florida, United States

Site Status

Local Institution - 176

Lakewood Rch, Florida, United States

Site Status

University of Miami Schiff Center for Liver Diseases

Miami, Florida, United States

Site Status

IMIC, Inc.

Palmetto Bay, Florida, United States

Site Status

Advanced Medical Research Center

Port Orange, Florida, United States

Site Status

Tampa General Hospital

Tampa, Florida, United States

Site Status

Gastrointestinal Specialists of Georgia, PC

Marietta, Georgia, United States

Site Status

Rush University Medical Center - University Cardiovascular Surgeons

Chicago, Illinois, United States

Site Status

University of Chicago Medicine

Chicago, Illinois, United States

Site Status

WestGlen Gastrointestinal Consultants, P.A.

Shawnee Mission, Kansas, United States

Site Status

Tulane University Health Sciences Center

New Orleans, Louisiana, United States

Site Status

Ochsner Medical Center

New Orleans, Louisiana, United States

Site Status

The Institute for Digestive Health & Liver Disease at Mercy Medical Center

Baltimore, Maryland, United States

Site Status

Digestive Disease Associates, PA

Catonsville, Maryland, United States

Site Status

Boston University Medical Center

Boston, Massachusetts, United States

Site Status

Beth Israel Deaconness Medical Center

Boston, Massachusetts, United States

Site Status

University of Michigan

Ann Arbor, Michigan, United States

Site Status

Henry Ford Hospital

Detroit, Michigan, United States

Site Status

University of Mississippi Medical Center

Jackson, Mississippi, United States

Site Status

Saint Louis University School of Medicine

St Louis, Missouri, United States

Site Status

University of Nebraska

Omaha, Nebraska, United States

Site Status

Beth Israel Medical Center

New York, New York, United States

Site Status

Concorde Medical Group

New York, New York, United States

Site Status

New York Presbyterian Hospital - Weill-Cornell

New York, New York, United States

Site Status

University of Rochester Medical Center

Rochester, New York, United States

Site Status

Local Institution - 102

Chapel Hill, North Carolina, United States

Site Status

UNC Hospitals GI Medicine Clinic

Chapel Hill, North Carolina, United States

Site Status

Duke University School of Medicine

Durham, North Carolina, United States

Site Status

Carolinas HealthCare System Digestive Health

Huntersville, North Carolina, United States

Site Status

Ohio State University Wexner Medical Center

Columbus, Ohio, United States

Site Status

University of Pittsburgh Medical Center - Center for Liver Diseases

Pittsburgh, Pennsylvania, United States

Site Status

University Gastroenterology

Providence, Rhode Island, United States

Site Status

ClinSearch LLC

Chattanooga, Tennessee, United States

Site Status

Gastro One

Germantown, Tennessee, United States

Site Status

Texas Clinical Research Institute LLC

Arlington, Texas, United States

Site Status

Liver Institute at Methodist Dallas

Dallas, Texas, United States

Site Status

UT Southwestern Medical Center

Dallas, Texas, United States

Site Status

Brooke Army Medical Center Francis Street Medical Center

Fort Sam Houston, Texas, United States

Site Status

Baylor College of Medicine - Baylor Heart Clinic

Houston, Texas, United States

Site Status

Houston Methodist Hospital

Houston, Texas, United States

Site Status

Digestive Health Associates of Texas (DHAT)

Rockwell, Texas, United States

Site Status

American Research Corporation

San Antonio, Texas, United States

Site Status

Intermountain Medical Center

Murray, Utah, United States

Site Status

University of Vermont Medical Center Gastro

Burlington, Vermont, United States

Site Status

Bon Secours Liver Institute of Hampton Roads

Newport News, Virginia, United States

Site Status

Digestive and Liver Disease Specialists

Norfolk, Virginia, United States

Site Status

Bon Secours Liver Institute of Richmond

Richmond, Virginia, United States

Site Status

McGuire Veterans Affairs Medical Center

Richmond, Virginia, United States

Site Status

Virginia Commonwealth University School of Medicine

Richmond, Virginia, United States

Site Status

University of Washington Harborview Medical Center

Seattle, Washington, United States

Site Status

Liver Institute Northwest PLLC

Seattle, Washington, United States

Site Status

University of Sydney - Royal Prince Alfred Hospital

Camperdown, New South Wales, Australia

Site Status

Nepean Hospital

Kingswood, New South Wales, Australia

Site Status

Royal Brisbane and Women's Hospital

Herston, Queensland, Australia

Site Status

Mater Hospital Brisbane

South Brisbane, Queensland, Australia

Site Status

The Alfred Hospital

Melbourne, Victoria, Australia

Site Status

University of Calgary, Cumming School of Medicine

Calgary, Alberta, Canada

Site Status

South Edmonton Gastroenterology

Edmonton, Alberta, Canada

Site Status

Vancouver General Hospital

Vancouver, British Columbia, Canada

Site Status

Toronto Center for Liver Disease - Francis Family Liver Clinic

Toronto, Ontario, Canada

Site Status

CHU d'Angers

Angers, , France

Site Status

Assistance Publique - Hopitaux de Paris - Hopital Beaujon

Clichy, , France

Site Status

Hopital de la Croix-Rousse

Lyon, , France

Site Status

Assistance Publique - Hopitaux de Paris - Hopital Cochin

Paris, , France

Site Status

Assistance Publique - Hopitaux de Paris - Hopital Universitaire Pitie Salpetriere

Paris, , France

Site Status

Hopital Haut Leveque

Pessac, , France

Site Status

Centre Hospitalier Universitaire de Rennes - Hopital de Pontchaillou

Rennes, , France

Site Status

Hopital Hautepierre

Strasbourg, , France

Site Status

Local Institution - 356

Strasbourg, , France

Site Status

Universitaetsklinikum der RWTH Aachen

Aachen, , Germany

Site Status

Johann Wolfgang Goethe University Hospital

Frankfurt am Main, , Germany

Site Status

Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz

Mainz, , Germany

Site Status

Universitaetsklinikum Muenster

Münster, , Germany

Site Status

Hamamatsu University Hospital

Hamamatsu, , Japan

Site Status

Local Institution - 604

Hamamatsu, , Japan

Site Status

Local Institution - 608

Kashihara, , Japan

Site Status

Nara Medical University Hospital

Kashihara, , Japan

Site Status

Local Institution - 601

Kawasaki, , Japan

Site Status

Shin-Yurigaoka General Hospital

Kawasaki, , Japan

Site Status

Kurume University Hospital

Kurume, Fukuoka, , Japan

Site Status

Local Institution - 607

Kurume, Fukuoka, , Japan

Site Status

Local Institution - 615

Kyoto, , Japan

Site Status

University Hospital, Kyoto Prefectural University of Medicine

Kyoto, , Japan

Site Status

Japanese Red Cross Musashino Hospital

Musashino, , Japan

Site Status

Local Institution - 602

Musashino, , Japan

Site Status

Aichi Medical University Hospital

Nagakute, , Japan

Site Status

Local Institution - 611

Nagakute, , Japan

Site Status

Local Institution - 603

Osaka-Fu, , Japan

Site Status

Osaka University Hospital OUH

Osaka-Fu, , Japan

Site Status

Local Institution - 613

Ōgaki, , Japan

Site Status

Ogaki Municipal Hospital

Ōgaki, , Japan

Site Status

Local Institution - 609

Saga, , Japan

Site Status

Saga University Hospital

Saga, , Japan

Site Status

Belland General Hospital

Sakaishi, , Japan

Site Status

Local Institution - 605

Sakaishi, , Japan

Site Status

Local Institution - 612

Suita, , Japan

Site Status

Saiseikai Suita Hospital

Suita, , Japan

Site Status

Local Institution - 600

Yokohama, Kanagawa, , Japan

Site Status

Yokohama City University Hospital

Yokohama, Kanagawa, , Japan

Site Status

Katowice (DRS)Synexus Polska Sp. z o.o. Oddzial w Katowicach

Katowice, , Poland

Site Status

Samodzielny Publiczny Centralny Szpital Kliniczny Im Prof. Kornela Gibinskiego

Katowice, , Poland

Site Status

Krakow Medical Center LLC

Krakow, , Poland

Site Status

Lodz (DRS)Synexus Polska Sp. Z o.o. Oddzial w Lodzi

Lodz, , Poland

Site Status

Wojewodzki Specjalistyczny Szpital im. dr Wladyslawa Bieganskiego

Lodz, , Poland

Site Status

ID Clinic

Mysłowice, , Poland

Site Status

Local Institution - 453

Mysłowice, , Poland

Site Status

Synexus SCM Sp. z o.o. Oddz. Warszawa

Warsaw, , Poland

Site Status

Soon Chun Hyang University Hospital Bucheon

Bucheon-si, , South Korea

Site Status

Hanyang University Seoul Hospital

Seoul, , South Korea

Site Status

Korea University Hospital at Guro

Seoul, , South Korea

Site Status

Boramae Medical Center

Seoul, , South Korea

Site Status

Seoul National University Hospital

Seoul, , South Korea

Site Status

Asan Medical Center

Seoul, , South Korea

Site Status

Yonsei University Wonju Severance Christian Hospital

Wŏnju, , South Korea

Site Status

Hospital Val d'Hebron

Barcelona, , Spain

Site Status

University Hospital of Girona Dr. Josep Trueta

Girona, , Spain

Site Status

Parc Tauli Hospital Universitari

Sabadell (Barcelona), , Spain

Site Status

Hospital Universitario Virgen Macarena

Seville, , Spain

Site Status

Hospital Virgen del Rocio

Seville, , Spain

Site Status

University of Birmingham Institute of Biomedical Research

Birmingham, , United Kingdom

Site Status

Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital

Cambridge, , United Kingdom

Site Status

Local Institution - 558

Hardwick, , United Kingdom

Site Status

North Tees (DRS) Synexus North Teesside Clinical Research Centre

Hardwick, , United Kingdom

Site Status

Local Institution - 556

Hexham, , United Kingdom

Site Status

Synexus Hexham Clinical Research Centre, Hexham (DRS)

Hexham, , United Kingdom

Site Status

Kings College Hospital

London, , United Kingdom

Site Status

Chelsea and Westminster Hospital NHS Foundation Trust - Chelsea and Westminster Hospital (CWH)

London, , United Kingdom

Site Status

Imperial College University Trust

London, , United Kingdom

Site Status

Local Institution - 559

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Canada France Germany Japan Poland South Korea Spain United Kingdom

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

U1111-1235-3234

Identifier Type: OTHER

Identifier Source: secondary_id

2018-004431-79

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CC-90001-NASH-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.